Toronto Dominion Bank Acquires 8,578 Shares of Illumina, Inc. (NASDAQ:ILMN)

Toronto Dominion Bank boosted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 38.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 30,838 shares of the life sciences company’s stock after acquiring an additional 8,578 shares during the quarter. Toronto Dominion Bank’s holdings in Illumina were worth $4,022,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Wealth Enhancement Advisory Services LLC raised its holdings in Illumina by 23.1% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 9,755 shares of the life sciences company’s stock valued at $1,018,000 after buying an additional 1,831 shares during the period. Blue Trust Inc. raised its stake in shares of Illumina by 2,203.6% in the second quarter. Blue Trust Inc. now owns 2,534 shares of the life sciences company’s stock valued at $264,000 after acquiring an additional 2,424 shares during the period. Sumitomo Mitsui Trust Holdings Inc. raised its stake in shares of Illumina by 3.6% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 399,966 shares of the life sciences company’s stock valued at $41,748,000 after acquiring an additional 13,725 shares during the period. Fifth Third Bancorp lifted its holdings in shares of Illumina by 13.6% in the 2nd quarter. Fifth Third Bancorp now owns 5,870 shares of the life sciences company’s stock worth $613,000 after acquiring an additional 704 shares during the last quarter. Finally, Brickley Wealth Management boosted its stake in shares of Illumina by 24.3% during the 2nd quarter. Brickley Wealth Management now owns 7,863 shares of the life sciences company’s stock worth $821,000 after purchasing an additional 1,539 shares during the period. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently weighed in on ILMN. Royal Bank of Canada increased their price objective on shares of Illumina from $252.00 to $254.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 5th. Canaccord Genuity Group increased their price target on Illumina from $130.00 to $145.00 and gave the stock a “hold” rating in a report on Tuesday, November 5th. JPMorgan Chase & Co. boosted their price objective on Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Stephens increased their target price on Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 12th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $156.00 target price on shares of Illumina in a research report on Tuesday, November 12th. Eight equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $165.95.

Illumina Trading Down 1.7 %

Shares of NASDAQ:ILMN opened at $143.87 on Monday. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. The company has a market capitalization of $22.82 billion, a PE ratio of -14.44 and a beta of 1.11. Illumina, Inc. has a 12-month low of $100.08 and a 12-month high of $156.66. The business’s fifty day simple moving average is $144.27 and its 200-day simple moving average is $128.63.

Illumina (NASDAQ:ILMN) last announced its earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.08 billion. During the same period in the previous year, the company posted $0.33 earnings per share. The firm’s revenue was down 3.5% on a year-over-year basis. As a group, equities research analysts predict that Illumina, Inc. will post 4.11 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.